Public Funding for Cardiology Devices Ltd

This project will advance the development of MyoCaid, an innovative new medical device to treat patients with advanced heart failure. Heart failure is the single biggest cause of death, and is responsible for approximately 60,000 deaths per year in the UK alone. Doctors have pills they can give to help patients with heart failure, but when heart failure becomes very severe, these pills are less effective, and sadly, the prognosis is often very poor. Cardiology Devices Limited is developing a new, mechanical treatment to both alleviate the symptoms, and prolong the life of patients with severe heart failure, so they can be treated with a device which helps the heart pump blood. In particular, this device is targetted at older, frailer patients who have had heart attacks who currently are normally not eligible for mechanical devices. Overall, this treatment aims to address the major health condition of heart failure by both alleviating symptoms and prolonging life, as well as address the underlying healthcare inequality which is inherent to the selection of appropriate patients for mechanical devices and heart transplantation. Cardiology Devices hopes that this treatment can become the standard of care for patients with severe heart failure, and we can give patients years or decades more of healthy, symptom free life, without needing a heart transplant, and without the complications of traditional mechanical devices.

Cardiovascular disease is the most common cause of death in the UK. After a heart attack, the heart is weaker, and struggles to pump blood around the body. This causes less blood to get to the kidneys and brain and whilst patients can take medications to help, they cannot make the heart return to normal, and sadly approximately 60,000 people in the UK per year still die from heart failure. This innovation is a device which cardiologists can insert relatively quickly and easily and works with the heart to improve the blood supply to the organs, and reduce the workload of the heart. It has the potential to either bridge patients to a heart transplant, or even for patients to live with for many years. This gives the potential for the heart to recover, or for them to live with for the rest of their lives, essentially curing them of end stage heart failure.